In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) reported that Garner William J. has picked up 612,393 of common stock as of 2017-06-12.
The acquisition brings the aggregate amount owned by Garner William J. to a total of 612,393 representing less than 4.5% stake in the company.
For those not familiar with the company, DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).
A glance at DelMar Pharmaceuticals Inc. (NASDAQ:DMPI)’s key stats reveals a current market capitalization of 25.77 Million based on 13.46 Million shares outstanding and a price at last close of $1.87 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-06-06, Bell picked up 10,000 at a purchase price of $2.12. This brings their total holding to 45,288 as of the date of the filing.
On the sell side, the most recent transaction saw Garner unload 10,000 shares at a sale price of $1.30. This brings their total holding to 10,000.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.